About: Transitional changes in the incidence of hip osteonecrosis among renal transplant recipients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Transitional changes in the incidence of hip osteonecrosis among renal transplant recipients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Transitional changes in the incidence of hip osteonecrosis among renal transplant recipients
Creator	Abe, Hirohito Hamada, Hidetoshi Sakai, Takashi Sugano, Nobuhiko Takahara, Shiro Takao, Masaki
Source	Elsevier; Medline; PMC
abstract	Abstract Background Immunosuppressive therapy for renal allograft recipients has changed substantially since the introduction of the anti-CD25 monoclonal antibody, basiliximab. We hypothesized that recent improvements in immunosuppressive treatment may reduce the incidence of osteonecrosis of the femoral head (ONFH). This study aimed to investigate transitional changes in the incidence of OFNH among renal transplant recipients by MRI. Methods Participants comprised 110 patients who had undergone renal transplantation from 2003 to 2012, during which time basiliximab was in regular use at our institute (Recent group), and 232 patients who had undergone RT between 1986 and 2003 (Past group). We compared ONFH incidence between the two groups and evaluated risk factors for ONFH, including immunosuppressants (calcineurin inhibitors, basiliximab, and/or steroids) and postoperative renal function. Results Incidence of ONFH was lower in the Recent group (0%) than in the Past group (3.4%; p = 0.043). In the Recent group, age was greater, ABO/human leukocyte antigen incompatibility was worse, while steroid dose was decreased and post-transplant renal function was improved. Cumulative methylprednisolone dose at postoperative week 2 and delayed graft function were identified as risk factors for ONFH. Conclusion Risk of ONFH after renal transplantation has fallen with the advent of regular use of basiliximab, although this agent does not appear to be a factor directly associated with the incidence of ONFH. Study design Clinical prognostic study (Level III case control study).
has issue date	2019-07-04(xsd:dateTime)
bibo:doi	10.1016/j.jos.2019.06.009
bibo:pmid	31280930
has license	els-covid
sha1sum (hex)	3fb9e68b962cbe9bb678fa69f66e77351bb27849
schema:url	https://doi.org/10.1016/j.jos.2019.06.009
resource representing a document's title	Transitional changes in the incidence of hip osteonecrosis among renal transplant recipients
has PubMed Central identifier	PMC7135379
has PubMed identifier	31280930
schema:publication	J Orthop Sci
resource representing a document's body	covid:3fb9e68b962cbe9bb678fa69f66e77351bb27849#body_text
is schema:about of	named entity 'renal transplantation' named entity 'basiliximab' named entity 'calcineurin inhibitors' named entity 'Cumulative' named entity 'human leukocyte antigen' named entity 'Recent' named entity 'incidence' named entity 'This' named entity 'transitional' named entity 'Results' named entity 'age' named entity 'Incidence' named entity 'renal function' named entity 'ADVENT' named entity 'REGULAR' named entity 'RECENT' named entity 'INSTITUTE' named entity 'A FACTOR' named entity 'APPEAR' named entity 'CLINICAL' named entity 'TREATMENT' named entity 'IDENTIFIED' named entity 'OUR' named entity 'METHODS' named entity 'TRANSITIONAL' named entity 'IMMUNOSUPPRESSIVE' named entity 'RISK FACTORS' named entity 'CONCLUSION' named entity 'USE OF' named entity 'RENAL TRANSPLANTATION' named entity 'AGE' named entity 'RISK OF' named entity 'PARTICIPANTS' named entity 'INHIBITORS' named entity 'GROUP' named entity '110' named entity 'RENAL FUNCTION' named entity 'WEEK 2' named entity 'INTRODUCTION' named entity 'CHANGED' named entity 'III' named entity 'REDUCE' named entity 'ABO' named entity '283' named entity 'WORSE' covid:arg/3fb9e68b962cbe9bb678fa69f66e77351bb27849 named entity 'ARTICLE' named entity 'PATIENTS' named entity 'GREATER' named entity 'DIRECTLY' named entity 'CASE CONTROL STUDY' named entity 'DOES NOT' named entity 'OSTEONECROSIS OF THE FEMORAL HEAD' named entity 'STEROIDS' named entity 'GROUPS' named entity 'DELAYED GRAFT FUNCTION' named entity 'EVALUATED' named entity 'STUDY' named entity 'BACKGROUND' named entity 'RESULTS' named entity 'STUDY DESIGN' named entity 'IMMUNOSUPPRESSIVE THERAPY' named entity 'MRI' named entity 'TIME' named entity 'AGENT' named entity 'RENAL' named entity 'INCLUDING' named entity 'CUMULATIVE' named entity 'ALLOGRAFT' named entity 'ASSOCIATED WITH' named entity 'PROGNOSTIC STUDY' named entity 'IMMUNOSUPPRESSANTS' named entity 'INCOMPATIBILITY' named entity 'POST-TRANSPLANT' named entity 'DECREASED' named entity 'BASILIXIMAB'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software